Apologies if this has been posted before it is the Abstract of...

Apologies if this has been posted before it is the Abstract of the Invitro trial of CF33- CD19 and Car T cells it was published on April 1 2024 in the Journal of the American college of Surgeons, SJ Price and Y Fong among the others listed

Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor - PubMed (nih.gov)


Conclusions: Engineered CF33-CD19t effectively infects and expresses CD19t in pancreatic tumors, triggering cell killing and increased immunogenic response by CD19-CAR T cells. Notably, CF33-CD19t can turn cold immunologic tumors hot, enabling solid tumors to be targetable by agents designed against liquid tumor antigens.

This trial was the pre human trial of Oncarlytics and First patient dosed in IV combo arm on 24th June 2024. First Patient in the Mono IV trial in February results due 4th Quarter 2024, that day is not far away can't wait in the trial results were measured at day 13 so we are way past that and they now know things. Wish I did!